Grantham, Mayo, Van Otterloo & Co (GMO)
MED icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Medifast MED Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,300
Closed -$288K – 567
2018
Q3 		$288K Sell
1,300
-3,800
-75% -$770K ﹤0.01% 486
2018
Q2 		$817K Sell
5,100
-800
-14% -$102K 0.01% 387
2018
Q1 		$551K Buy
+5,900
New +$441K ﹤0.01% 473

Other funds holding MED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s MED Position: Q4 2018 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Medifast (MED) in Q4 2018, closing a stake of 1,300 shares — an estimated $288K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in MED in Q1 2018 and held it in 3 quarters. The position peaked at $817K in Q2 2018. 247 funds tracked by Wall St. Rank hold MED as of Q4 2018.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Medifast position as of Q4 2018 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 1,300 Medifast shares in Q4 2018, an estimated $288K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Medifast in Q1 2018 and held it in 3 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Medifast position peaked at $817K in Q2 2018.
  • 247 funds tracked by Wall St. Rank held Medifast as of Q4 2018.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2018, filed 13 Feb 2019.